Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)

Trial Profile

Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary) ; Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Acronyms checkmate744
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 16 Mar 2017 Planned End Date changed from 1 Feb 2022 to 1 Mar 2022.
    • 16 Mar 2017 Planned primary completion date changed from 1 Feb 2021 to 1 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top